Title
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease
Phase
Phase 3Lead Sponsor
La Jolla Pharmaceutical CompanyStudy Type
InterventionalStatus
Completed No Results PostedIntervention/Treatment
abetimus ...Study Participants
330The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.
LJP 394 (abetimus sodium) is a unique drug that is specifically designed to lower production of antibodies to double-stranded DNA. These antibodies are believed to contribute to kidney damage in patients with Systemic Lupus Erythematosus (SLE). Rising levels of these antibodies seem to be associated with exacerbations of kidney disease that are known as "renal flares." Currently, anti-inflammatory and cytotoxic drugs are used to treat renal flares. Unfortunately, these drugs are often associated with certain unpleasant side effects. The purpose of this trial is to determine whether LJP 394 can delay or reduce the number of renal flares. It is possible that if renal flares can be delayed or reduced, patients may be able to take smaller amounts of anti-inflammatory or cytotoxic drugs and therefore suffer fewer of the side effects associated with these treatments.
Inclusion Criteria Diagnosed with SLE Historical evidence of SLE renal disease Elevated levels of dsDNA antibodies Weight of 40 kg or greater Exclusion Criteria Active SLE renal disease Use of certain anti-inflammatory or cytotoxic therapies or therapeutic interventions during the months immediately before dosing Clinical laboratory test values outside of certain limits Malignant disease or immunodeficiency syndrome Acute or chronic infections History of serious heart disease
